Precision Biosciences Inc (DTIL)

$4.42 +0.12 (2.79%)
Market Cap 57.01M
Revenue (ttm) 68.70M
Net Income (ttm) 7.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 10.44%
Debt to Equity Ratio 1.35
Volume 412,500
Avg Vol 224,090
Day's Range N/A - N/A
Shares Out 13.26M
Stochastic %K 31%
Beta 1.11
Analysts Strong Sell
Price Target $32.50

Company Profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with t...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 314 5512
Fax: 480 393 5553
Address:
302 East Pettigrew St., Suite A-100, Durham, United States
Impatient_Investor
Impatient_Investor Dec. 31 at 3:33 PM
$DTIL
0 · Reply
LoveRetailFroth
LoveRetailFroth Dec. 30 at 9:08 PM
$RARE Added a boatload of Bios $RNAC $DTIL $PALI $RCKT & IOVA for 2026 🍺
0 · Reply
LoveRetailFroth
LoveRetailFroth Dec. 30 at 7:06 PM
$RARE 2026 will be 2021 for many of these Bios🍺 $IOVA $RNAC $AMLX $DTIL
2 · Reply
Impatient_Investor
Impatient_Investor Dec. 30 at 5:48 PM
$DTIL
0 · Reply
LoveRetailFroth
LoveRetailFroth Dec. 30 at 4:46 PM
$RARE 💎s $PALI $DTIL $RNAC $AMLX 🚀🥪
0 · Reply
JohnTrack
JohnTrack Dec. 30 at 3:16 PM
$DTIL watching opening prints!
0 · Reply
JohnTrack
JohnTrack Dec. 30 at 1:11 PM
$DTIL fresh buzz... https://www.rapidticker.com/news/dtil-sec-filing-b911db
0 · Reply
Wisenheimer
Wisenheimer Dec. 29 at 6:09 PM
$DTIL
0 · Reply
Impatient_Investor
Impatient_Investor Dec. 29 at 4:12 PM
$DTIL
0 · Reply
hrnsh
hrnsh Dec. 29 at 12:02 PM
$DTIL
0 · Reply
Latest News on DTIL
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

Dec 29, 2025, 3:40 AM EST - 2 days ago

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Dec 23, 2025, 7:00 AM EST - 8 days ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision Biosciences: Still Swinging And Finally Drawing Blood

Dec 4, 2025, 6:38 AM EST - 27 days ago

Precision Biosciences: Still Swinging And Finally Drawing Blood

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Nov 19, 2025, 7:01 AM EST - 6 weeks ago

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript

Nov 11, 2025, 4:11 PM EST - 7 weeks ago

Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Nov 10, 2025, 6:12 PM EST - 7 weeks ago

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Nov 10, 2025, 5:21 PM EST - 7 weeks ago

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 7:01 AM EST - 2 months ago

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 31, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Oct 14, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Oct 9, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Oct 7, 2025, 7:01 AM EDT - 3 months ago

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

Sep 30, 2025, 7:01 AM EDT - 3 months ago

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 16, 2025, 5:52 AM EDT - 3 months ago

Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Sep 12, 2025, 7:01 AM EDT - 3 months ago

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Sep 8, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Aug 6, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

Aug 4, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jul 23, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

Jul 16, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jun 25, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 14, 2025, 4:30 PM EDT - 8 months ago

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

May 8, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

May 7, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 1, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Apr 15, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Mar 21, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Mar 20, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 19, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Mar 17, 2025, 7:01 AM EDT - 10 months ago

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Mar 12, 2025, 8:00 AM EDT - 10 months ago

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 24, 2025, 7:01 AM EST - 11 months ago

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Feb 19, 2025, 2:27 PM EST - 11 months ago

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Feb 19, 2025, 7:01 AM EST - 11 months ago

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Jan 29, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Jan 10, 2025, 2:18 PM EST - 1 year ago

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 10:01 AM EST - 1 year ago

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 8:00 AM EST - 1 year ago

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Dec 18, 2024, 7:01 AM EST - 1 year ago

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming November Investor Conferences

Nov 21, 2024, 7:01 AM EST - 1 year ago

Precision BioSciences to Participate in Upcoming November Investor Conferences

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Nov 15, 2024, 7:00 AM EST - 1 year ago

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 7:01 AM EST - 1 year ago

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Oct 29, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Oct 28, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Oct 24, 2024, 4:15 PM EDT - 1 year ago

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Oct 24, 2024, 8:47 AM EDT - 1 year ago

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Impatient_Investor
Impatient_Investor Dec. 31 at 3:33 PM
$DTIL
0 · Reply
LoveRetailFroth
LoveRetailFroth Dec. 30 at 9:08 PM
$RARE Added a boatload of Bios $RNAC $DTIL $PALI $RCKT & IOVA for 2026 🍺
0 · Reply
LoveRetailFroth
LoveRetailFroth Dec. 30 at 7:06 PM
$RARE 2026 will be 2021 for many of these Bios🍺 $IOVA $RNAC $AMLX $DTIL
2 · Reply
Impatient_Investor
Impatient_Investor Dec. 30 at 5:48 PM
$DTIL
0 · Reply
LoveRetailFroth
LoveRetailFroth Dec. 30 at 4:46 PM
$RARE 💎s $PALI $DTIL $RNAC $AMLX 🚀🥪
0 · Reply
JohnTrack
JohnTrack Dec. 30 at 3:16 PM
$DTIL watching opening prints!
0 · Reply
JohnTrack
JohnTrack Dec. 30 at 1:11 PM
$DTIL fresh buzz... https://www.rapidticker.com/news/dtil-sec-filing-b911db
0 · Reply
Wisenheimer
Wisenheimer Dec. 29 at 6:09 PM
$DTIL
0 · Reply
Impatient_Investor
Impatient_Investor Dec. 29 at 4:12 PM
$DTIL
0 · Reply
hrnsh
hrnsh Dec. 29 at 12:02 PM
$DTIL
0 · Reply
AndreaRR
AndreaRR Dec. 29 at 9:56 AM
$DTIL
0 · Reply
Stmkr
Stmkr Dec. 29 at 8:56 AM
$DTIL https://seekingalpha.com/article/4856121-precision-biosciences-potential-proof-of-concept-data-for-hbv-cure-in-2026
0 · Reply
OnyxOmen
OnyxOmen Dec. 27 at 10:09 AM
$DTIL Trading dynamics suggest reliability now matters more than momentum bursts. Efficiency gains must convert into measurable results. Execution consistency is the fastest path to confidence rebuilding. Patience is warranted — but must be supported by results.
0 · Reply
Portfoliovalue1
Portfoliovalue1 Dec. 24 at 7:28 PM
$DTIL Merry Christmas and Happy New Year to HBV therapy followers! Good luck on this interesting stock on 2026 and make plenty of money!
1 · Reply
AndreaRR
AndreaRR Dec. 24 at 8:23 AM
$DTIL
0 · Reply
Impatient_Investor
Impatient_Investor Dec. 24 at 7:04 AM
$DTIL
1 · Reply
SuperGreenToday
SuperGreenToday Dec. 23 at 7:30 PM
$DTIL Share Price: $4.22 Contract Selected: May 15, 2026 $5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.08 Potential Upside: 54% ROI Time to Expiration: 142 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Impatient_Investor
Impatient_Investor Dec. 23 at 4:09 PM
$DTIL @Scrood_the_Pooch paid pumper, are you there?. Below 3 soon.
0 · Reply
Impatient_Investor
Impatient_Investor Dec. 18 at 8:15 PM
$DTIL
0 · Reply
Phantom_Vortex_9608
Phantom_Vortex_9608 Dec. 17 at 12:08 PM
$DTIL biotech with gene editing angle, higher lows into a catalyst window can offer strong asymmetry if volume confirms
0 · Reply
Estimize
Estimize Dec. 17 at 11:00 AM
Wall St is expecting -0.26 EPS for $DTIL Q4 [Reporting 03/17 BMO] http://www.estimize.com/intro/dtil?chart=historical&metric_name=eps&utm_c
0 · Reply
hrnsh
hrnsh Dec. 17 at 3:10 AM
$DTIL
1 · Reply